MedTrace Logo

Automatic Evaluation of the Severity of Gastric Intestinal Metaplasia With Pathology Artificial Intelligence Diagnosis System

NCT05447221 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-09-06

No results posted yet for this study

Summary

The OLGIM staging system is highly recommended for a comprehensive assessment of GIM severity to evaluate patients' gastric cancer risk. However, its need to take at least 4 biopsies is not clinically feasible due to a serious shortage of pathologists compared with the large number of gastric cancer screening population.

We plan to develop a Digital Pathology artificial intelligence diagnosis system (DPAIDS), to automatically identify tumor areas in whole slide images(WSI) and quickly and accurately quantify the severity of intestinal metaplasia according to the proportion of intestinal metaplasia areas.

Conditions

  • Gastric Intestinal Metaplasia
  • Artificial Intelligence
  • Pathology
  • Gastric Cancer

Interventions

DIAGNOSTIC_TEST

The diagnosis of Artificial Intelligence and pathologists

Pathologists and AI will assess the severity of intestinal metaplasia and judge the tumor area of whole slide images of gastric biopsy specimens independently. In addition, the pathologists can not see the diagnosis of AI.

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • Yanqing Li, MD, PhD · Qilu Hospital, Shandong University

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05447221 on ClinicalTrials.gov